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Abstract
Background: ODM-201, a new-generation androgen receptor inhibitor, has shown clinical
efficacy in prostate cancer (PCa). Quantitative methods are needed to accurately assess
changes in bone as a measurement of treatment response. The Bone Scan Index (BSI) reflects
the percentage of skeletal mass a given tumour affects.
Objective: To evaluate the predictive value of the BSI in metastatic castration-resistant PCa
(mCRPC) patients undergoing treatment with ODM-201.
Design, setting, and participants: From a total of 134 mCRPC patients who participated in the
Activity and Safety of ODM-201 in Patients with Progressive Metastatic Castration-resistant
Prostate Cancer clinical trial and received ODM-201, we retrospectively selected all those
patients who had bone scan image data of sufficient quality to allow for both baseline and
12-wk follow-up BSI-assessments (n = 47). We used the automated EXINI bone BSI software
(EXINI Diagnostics AB, Lund, Sweden) to obtain BSI data.
Outcome measurements and statistical analysis: We used the Cox proportional hazards
model and Kaplan-Meier estimates to investigate the association among BSI, traditional
clinical parameters, disease progression, and radiographic progression-free survival (rPFS).
Results and limitations: In the BSI assessments, at follow-up, patients who had a decrease or
at most a 20% increase from BSI baseline had a significantly longer time to progression in
bone (median not reached vs 23 wk, hazard ratio [HR]: 0.20; 95% confidence interval [CI],
0.07–0.58; p = 0.003) and rPFS (median: 50 wk vs 14 wk; HR: 0.35; 95% CI, 0.17–0.74;
p = 0.006) than those who had a BSI increase >20% during treatment.
Conclusions: The on-treatment change in BSI was significantly associated with rPFS in
mCRPC patients, and an increase >20% in BSI predicted reduced rPFS. BSI for quantification
of bone metastases may be a valuable complementary method for evaluation of treatment
response in mCRPC patients.
Patient summary: An increase in Bone Scan Index (BSI) was associated with shorter time to
disease progression in patients treated with ODM-201. BSI may be a valuable method of
complementing treatment response evaluation in patients with advanced prostate cancer.
# 2016 European Association of Urology. Published by Elsevier B.V. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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E U R O P E A N U R O L O G Y F O C U S 2 ( 2 0 1 6 ) 5 4 7 – 5 5 2548Fig. 1 – Flowchart showing the distribution of patients participating in
the study.
ARADES = Activity and Safety of ODM-201 in Patients with Progressive
Metastatic Castration-resistant Prostate Cancer.1. Introduction
Prostate cancer (PCa) is the most common primary cancer in
men in Europe and the second-most common cause of
cancer death in the European male population [1]. Despite
initial treatment in the early stages of the disease, many
patients still progress to metastatic castration-resistant PCa
(mCRPC) [2]. This phase is characterised by a persistent,
high-level androgen receptor (AR) function and has been
related to lower survival rates [3]. AR signalling can be
targeted at different levels, and its inhibition is the aim of
the development of new drugs [4]. ODM-201, a potent oral,
new-generation androgen inhibitor, binds to the AR with
high affinity and inhibits the receptor function by blocking
its nuclear translocation. ODM-201 recently showed
encouraging results in a phase 1 and 2 clinical trial (Activity
and Safety of ODM-201 in Patients with Progressive
Metastatic Castration-resistant Prostate Cancer, or ARADES)
in patients with progressive mCRPC. The drug is well
tolerated and exhibits high antitumour activity in both
chemotherapy-naı¨ve patients (prechemotherapy) and che-
motherapy-treated patients (postchemotherapy) [5].
Biomarkers are measurable parameters with an impor-
tant role in the prognostic evaluation of PCa patients when
predicting the response to treatments and monitoring the
disease. The Bone Scan Index (BSI) is a recently validated
imaging biomarker and the most objective quantification
method currently available for measuring tumour burden in
bone [6]. It represents the percentage of the total skeletal
mass affected by metastasis, and it can be calculated
automatically from images acquired in bone scintigraphy,
the most widely used imaging modality in this group of
patients [7]. The value of the BSI has been studied in mCRPC
patients treated with docetaxel [8] and more recently in the
context of a randomised, phase 2, placebo-controlled trial of
mCRPC patients treated with tasquinimod [9], showing that
the BSI strongly correlates with overall survival (OS). The
definition of end points is of the utmost importance in clinical
trials, and in daily clinical practice, end points earlier than OS
could have added value, for example, in decisions about
whether to continue or change treatment at earlier stages
[10].
In mCRPC, bone is the most commonly affected tissue,
and clinical or biologic parameters related to bone
metastases have a major prognostic value [11]. Therefore,
the study of an objective biomarker such as the BSI was of
interest for the evaluation of patients with bone metastasis
undergoing ODM-201 treatment. Thus, in this group of
patients, we decided to study the prognostic value of
tumour status in bone pre- and posttreatment. As far as we
know, this is the first report of the BSI used for patients
undergoing AR inhibitor treatment as part of a clinical trial.
The aim of this study was to evaluate the prognostic value of
the BSI at baseline and the value of on-treatment change in
the BSI from baseline as a biomarker of response to
treatment with ODM-201 in mCRPC patients. We also
studied possible associations between the BSI and other
prognostic biomarkers, such as prostate-specific antigen
(PSA), circulating tumour cells (CTC) count, and CTCconversion, as well as the value of the BSI in predicting
time to radiologic progression in soft and bone tissue and
radiographic progression-free survival (rPFS).
2. Materials and methods
2.1. Patient cohort
This study was carried out based on the ARADES clinical trial, which
was an open-label phase 1 and 2 multicentre trial with long-term
follow-up [5]. Patients were enrolled at 23 hospitals in Europe and the
United States. All 134 patients presented with histologically confirmed
adenocarcinoma of the prostate and progressive metastatic disease
despite ongoing androgen-deprivation therapy, serum testosterone
concentrations < 1.7 nmol/l, and an Eastern Cooperative Oncology
Group performance status of 0 or 1. None of the patients had received
previous therapy with enzalutamide or any other investigational AR
inhibitor. During the ARADES trial, patients received ODM-201 and
were stratified into three groups based on previous treatment received:
prechemotherapy/cytochrome P17 inhibitor (CYP17i) naive (n = 42),
postchemotherapy/CYP17i naı¨ve (n = 35), and post-CYP17i (n = 57).
From a total of 134 mCRPC patients who participated in the ARADES
clinical trial, 51 had bone scans obtained for central review. Of these
51 patients, 47 had bone scan image data of sufficient quality to allow for
retrospective baseline and 12 wk of follow-up BSI assessments. This last
group represents the BSI study group. Among these 47 patients, 36 had
bone metastases verified at inclusion in the ARADES trial (Fig. 1). We
conducted this study in accordance with the Declaration of Helsinki, and
it was approved by the investigational review board of each centre
participating in the ARADES trial.
2.2. Data management
Bone scan data obtained for central review were transferred to Ska˚ne
University Hospital, Malmo¨, Sweden, for BSI analysis. The BSI value was
Table 1 – Patient characteristics
Progressive mCRPC patients BSI data (n = 47), n (%) Total (n = 134), n (%)
Age, yr, median (range) 68.0 (55–82) 69.0 (53–89)
ECOG
0 (Fully active) 29 (62) 72 (54)
1 (Restricted) 18 (38) 62 (46)
Baseline PSA, ng/ml, median (range) 83.1 (4–1294) 98.9 (3–5000)
CTC count, no. (%):
<5 cells per 7.5 ml blood 25 (57) 65 (53)
5 cells per 7.5 ml blood 19 (43) 57 (47)
NA 3 12
Haemoglobin, g/l, median (range) 126 (72–152) 127 (72–152)
Albumin, g/l, median (range) 38 (28–51) 39 (23–51)
Serum alkaline phosphatase, U/l, median (range) 81.0 (40–568) 105.5 (39–1867)
Lactate dehydrogenase, U/l, median (range) 232.6 (147–491) 226.5 (145–598)
BSI = Bone Scan Index; CTC = circulating tumour cells; ECOG = Eastern Cooperative Oncology Group; mCRPC = metastatic castration-resistant prostate cancer;
NA = not applicable; PSA = prostate-specific antigen.
Fig. 2 – Kaplan-Meier curves showing patient time to progression in
bone stratified by Bone Scan Index values at baseline, before treatment.
BSI = Bone Scan Index; CI = confidence interval; NR = not reached.
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(EXINI Diagnostics AB, Lund, Sweden). The image data analysis was
performed independently by two experienced bone scan reviewers in
a blinded fashion, without any knowledge of clinical data. Each
reviewer could, if necessary, manually correct misclassifications of
hotspots. A consensus was used in cases of inconsistent BSI results
among reviewers, and the final BSI data were used in the statistical
analysis.
At baseline, we used a threshold of BSI = 1.0, which has been used in
previous studies [9,12,13], to stratify patients. At follow-up, we used a
BSI value increase from baseline to follow-up of at least 0.01 to stratify
the patients according to the presence or absence of any BSI value
change. When evaluating BSI percentage change, we used the threshold
of a 20% BSI increase to stratify patients. We chose this last value based
on close approximation to the median BSI percentage change value.
Clinical data (age, PSA, and CTC count) were derived from the ARADES
database at Orion Pharma (Espoo, Finland).
2.3. Outcome measures
We used the following five outcome measures in the statistical
analysis [5]: (1) PSA progression was defined as a PSA increase >25%
and >2 ng/ml above the documented nadir in two consecutive
visits at least 3 wk apart; (2) disease progression in soft tissue was
defined by modified Response Evaluation Criteria in Solid Tumors
(version 1.1) [14]; (3) disease progression in bone was defined by two
or more new lesions identified on 12-wk bone scans; (4) time to
progression in bone was defined by time in months to disease
progression in bone; and (5) radiographic progression-free survival
was defined by time in months to progression in bone and/or soft
tissue or death.
2.4. Statistical analysis
We assessed the association between BSI value and the other prognostic
biomarkers by using Cox proportional hazards regression models and
Kaplan-Meier estimates of the progression curves. We used two
methods, Pearson and Spearman, to evaluate the correlations between
baseline BSI value and the change in BSI value from baseline (expressed
as BSI unit difference or percentage change) with the other prognostic
biomarkers: PSA percentage change, soft tissue response, CTC change
from baseline, CTC percentage change, and CTC conversion rate. The
statistical calculations were performed using SAS version 9.4 for
Windows (SAS Institute, Cary, NC, USA).3. Results
The patient characteristics of the total ARADES population
(n = 134) and of the BSI study group (n = 47) are sum-
marised in Table 1. The BSI study group was well balanced
and showed baseline characteristics similar to those of the
total study population [5]. These 47 patients had received
previous treatment as follows: prechemotherapy/CYP17i
naive (n = 20), postchemotherapy/CYP17i naive (n = 16),
and post-CYP17i (n = 11). BSI analysis by the blinded bone
scan reviewers produced a high level of agreement, showing
an identical outcome in all but a few (<5%) cases for which
consensus among readers was reached.
Baseline BSI values ranged between 0 and 9.6 (median:
0.5 [standard deviation (SD): 2.5]). When analysing the
BSI study group (n = 47), patients with a baseline BSI value
<1 (n = 28) had a significantly longer median time to
progression in bone than patients with a baseline BSI value
>1 (n = 19; median not reached [NR] vs 35 wk; hazard ratio
[HR]: 0.25; 95% confidence interval [CI], 0.09–0.66;
p = 0.006) (Fig. 2). PSA percentage change from baseline,
soft tissue response, bone response, and CTC conversion did
not correlate with BSI values at baseline, but CTC change
Table 2 – Pearson and Spearman correlations (p value) of Bone Scan Index and other prognostic biomarkers in the follow-up group
Pearson and Spearman correlations
among variables
Baseline BSI,
r value (p value)
BSI change from baseline,
r value (p value)
BSI percentage change from baseline,
r value (p value)
Soft tissue response (n = 17) 0.21 (0.422) 0.50 (0.042) 0.51 (0.038)
0.13 (0.631) 0.61 (0.010) 0.70 (0.002)
Bone response (n = 36) 0.22 (0.201) 0.37 (0.024) 0.14 (0.387)
0.23 (0.178) 0.23 (0.178) 0.16 (0.345)
CTC change from baseline (n = 29) 0.10 (0.619) 0.66 (<0.001) 0.14 (0.477)
S0.40 (0.031) 0.16 (0.407) 0.47 (0.011)
PSA percentage change from baseline (n = 36) 0.07 (0.691) 0.14 (0.404) 0.76 (<0.001)
0.14 (0.428) 0.12 (0.483) 0.42 (0.010)
CTC percentage change from baseline (n = 24) 0.15 (0.480) 0.37 (0.071) 0.62 (0.001)
0.21 (0.315) 0.32 (0.131) 0.28 (0.190)
CTC conversion (n = 29) 0.01(0.971) 0.32 (0.094) 0.67 (<0.001)
0.06 (0.759) 0.34 (0.070) 0.50 (0.005)
BSI = Bone Scan Index; CTC = circulating tumour cells; PSA = prostate-specific antigen.
Fig. 4 – Kaplan-Meier curves showing patient time to progression in
bone stratified by Bone Scan Index percentage change from baseline
after 12 wk of treatment.
BSI = Bone Scan Index; CI = confidence interval; NR = not reached.
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at baseline when using Spearman’s correlation coefficient
measure (r = 0.40; p = 0.03) (Table 2).
BSI value change from baseline also correlated with time
to progression in bone when analysing the BSI study group
(n = 47); patients who had a decrease or no increase in BSI
value during the study (n = 17) had a significantly longer
time to progression in bone than those showing an increase
in BSI value of at least 0.01 from baseline to follow-up
(n = 30) (median NR vs 39 wk; HR: 0.24; 95% CI, 0.07–0.84;
p = 0.025) (Fig. 3). PSA progression did not show a
significant statistical correlation with BSI value change,
but using the Pearson correlation, soft tissue response and
CTC change from baseline were correlated with BSI value
change from baseline (r = 0.50, p = 0.042, and r = 0.66,
p < 0.001, respectively) (Table 2).
When analysing the BSI study group (n = 47), a decrease
in BSI percentage change or an increase in BSI percentage
change from baseline to follow-up of up to 20% (n = 27) was
associated with a significantly longer median time to
progression in bone (Fig. 4) and rPFS (Fig. 5) than an
increase >20% (n = 20; median NR vs 23 wk; HR: 0.2; 95% CI,
0.07–0.58; p = 0.003 and median 50 wk vs 14 wk; HR: 0.35;
95% CI, 0.17–0.74; p = 0.006, respectively). PSA progressionFig. 5 – Kaplan-Meier curves showing patient radiographic progression-
free survival stratified by Bone Scan Index percentage change from
baseline after 12 wk of treatment.
BSI = Bone Scan Index; CI = confidence interval; NR = not reached.
Fig. 3 – Kaplan-Meier curves showing patient time to progression in
bone stratified by Bone Scan Index change from baseline after 12 wk of
treatment.
CI = confidence interval; NR = not reached.did not show a significant statistical correlation with BSI
percentage change (p = 0.133).
Patients who presented with a BSI value >0 before ODM-
201 treatment initiation (n = 36) showed baseline BSI values
Fig. 6 – Kaplan-Meier curves showing patient time to prostate-specific
antigen progression stratified by Bone Scan Index changes at follow-up
after 12 wk of treatment initiation in the chemotherapy/CYP17i–naı¨ve
patient subgroup.
BSI = Bone Scan Index; CI = confidence interval; NR = not reached.
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BSI percentage change from baseline in this group ranged
between 21% and 473% (median: 30% [SD: 93]). Using the
Pearson correlation, BSI percentage change significantly
correlated with PSA percentage change (r = 0.76; p < 0.001),
disease progression in soft tissue (r = 0.51; p = 0.038), CTC
percentage change (r = 0.62; p = 0.001), and CTC conversion
rate (r = 0.67; p < 0.001) (Table 2).
When analysing all subgroups with different pretreat-
ments, among the prechemotherapy/CYP17i–naı¨ve patients
(n = 20), 15 patients showed a decrease or only a small
increase in BSI percentage change from baseline to follow-
up, at most 20%. These patients had a significantly longer
time to PSA progression (median: 72 wk vs 25 wk; HR: 0.2;
95% CI, 0.05–0.83; p = 0.027) (Fig. 6) than those with an
increase >20% (n = 5). Patients from the other two
pretreatment subgroups—postchemotherapy/CYP17i naı¨ve
(n = 16) and post-CYP17i (n = 11)—did not show significant
differences in time to PSA progression related to BSI
percentage change (p = 0.34 and p = 0.99, respectively).
4. Discussion
The present study shows that mCRPC patients with a
baseline BSI value >1 had a significantly shorter median
time to progression in bone involvement than mCRPC
patients with a baseline BSI value 1. We was also observed
that patients with a decrease or at most a 20% increase from
baseline BSI value had a significantly longer time to
progression in bone and rPFS than those with an on-
treatment BSI increase >20% during treatment. In the
subpopulation of prechemotherapy/CYP17i–naı¨ve patients,
those who had only small on-treatment increases (<20%) in
BSI value had a significantly longer time to PSA progression
than when analysing all the subgroups together.
Results from the present study are in accordance
with previous studies showing that baseline BSI values
could be used as a prognostic biomarker in PCa [6,12,13].Furthermore, this study supports the use of the BSI for
treatment monitoring as indicated by previously observed
strong correlations between BSI value changes from baseline
and survival in PCa at different disease stages [8,9,12,15]. The
present study adds to previous results suggestive of the
clinical utility of the BSI in advanced PCa as an adjunct to
established biomarkers. It could be of value for patient
stratification and for quantitative assessment of treatment
effects on bone metastases in clinical trials on top of known
clinical and biologic parameters with prognostic value
[11,16].
As the number of emerging candidate drugs for the
treatment of mCRPC rapidly increases, new tools are needed
to identify target patient populations more objectively and
reproducibly and to individualise treatment. The use of the
BSI at baseline as a prognostic tool for better risk stratification
before treatment decisions has now been demonstrated in
different studies [6,12,13]. There is also a need for tools that
assist an the objective follow-up of bone status after
treatment initiation. Use of the BSI during treatment could
guide clinicians in identifying which patients would benefit
from a certain therapy and should remain on treatment and
which patients would no longer benefit from treatment and
therefore should be offered other types of therapy. In clinical
trials, parameters with demonstrated surrogacy to OS are
desperately needed in CRPC, and change in BSI values during
treatment is a potential candidate.
The limitations of the bone scintigraphic technique
itself include the risk of false-positive signals caused by a
flare reaction induced by the initiation of a new treatment.
Flare phenomena occur most commonly during the first 3 mo
of treatment, but the duration of this local reaction in bone
tissue after induced cell death may vary. Therefore, we
decided to include only patients who had a follow-up bone
scan at 12 wk or more from the start of treatment with ODM-
201 in accordance with the Prostate Cancer Working Group
2 guidelines [17]. Despite precautions taken to avoid false
positive-signals because of flare and despite the absence of
any such signs upon visual inspection of the bone scans, the
influence of flare phenomena cannot completely be ruled out
in this investigation. In future studies, it may be advisable to
include a further follow-up bone scan examination at 6 or
9 mo after treatment initiation.
Patients were enrolled at 23 different hospitals in Europe
and the United States, and this could partially explain the
heterogeneity of the image data in both bone scans and
computed tomography scans. The low number of evaluable
images of sufficient quality resulted in a reduced number of
observations, which could in some cases have limited the
power to detect statistically significant differences. In future
studies, it may be advisable to include specific resolution
requirements in the image protocol for further imaging
analysis.
Because the BSI enables us to quantify the tumour
burden in bone and its changes after therapy, it is a useful
imaging biomarker that could be used to enhance the
prognostic evaluation of patients undergoing clinical trials.
Despite the increasing number of available biomarkers in
the field of PCa research, there is still a need for more
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only for research purposes but also for routine clinical
situations when stratifying the patient population and
monitoring the response to treatment given. Therefore,
further investigation is warranted of the BSI in the context
of prospective clinical studies.
5. Conclusions
The BSI measured at baseline is related to median time to
progression in bone in mCRPC patients treated with ODM-
201, and on-treatment increases in BSI values is associated
with a shorter time to PSA progression, a shorter time to
progression of the disease in bone, and a shorter rPFS. The
BSI as an imaging biomarker for quantification of bone
metastases could be a valuable complement to traditional
methods for evaluation of treatment response in mCRPC
patients undergoing clinical trials.
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